Description

Product Description

Tegafur is a synthetic fluoropyrimidine derivative designed for laboratory and preclinical cancer research. As a prodrug of 5-fluorouracil (5-FU), it undergoes enzymatic conversion in the liver to release the active metabolite, which inhibits thymidylate synthase, leading to impaired DNA replication and RNA function in rapidly proliferating cells.

In vitro and in vivo studies show that Tegafur effectively induces S-phase cell cycle arrest and triggers apoptosis in various tumor cell lines. Its pharmacokinetic properties allow prolonged systemic exposure to the active 5-FU metabolite, facilitating mechanistic studies of cytotoxicity, DNA damage responses, and nucleic acid metabolism.

Tegafur is commonly used in combination with other chemotherapeutic agents to investigate synergistic effects, drug resistance mechanisms, and novel therapeutic strategies in oncology research. The compound’s solubility in DMSO and other polar solvents makes it suitable for cell culture, enzyme assays, and preclinical animal studies. Tegafur serves as an important tool for cancer biologists studying fluoropyrimidine-based chemotherapy and its molecular targets.

Product Specifications

Mechanism of Action

Tegafur is converted enzymatically to 5-fluorouracil (5-FU) in vivo, which then inhibits thymidylate synthase. This inhibition prevents the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), disrupting DNA synthesis. Additionally, 5-FU can be incorporated into RNA, altering RNA processing and function.

1. DNA Synthesis Inhibition
   Tegafur-derived 5-FU selectively targets rapidly dividing cells by impairing DNA replication.

2. Cell Cycle Arrest
   Induces S-phase arrest in proliferating cells, allowing detailed studies of cell cycle checkpoints.

3. Apoptosis Induction
   Activation of DNA damage response pathways leads to programmed cell death in tumor models.

4. Combination Research
   Frequently combined with other chemotherapeutics in preclinical studies to evaluate synergistic cytotoxicity and mechanisms of drug resistance.

   

Side Effects (Research Context)

In controlled laboratory experiments, Tegafur demonstrates cytotoxicity in tumor cells, as expected for an antimetabolite. Researchers should handle the compound with care, using PPE and biosafety protocols. It is not intended for human or veterinary use. Variations in concentration, solvent, and experimental conditions may affect cell viability and study outcomes.

Keywords

Tegafur, 5-FU prodrug, antimetabolite, DNA synthesis inhibitor, S-phase arrest, apoptosis research, chemotherapeutic research chemical, cancer research, factory research chemical supplier, high purity compound, laboratory study, preclinical oncology

Shipping Guarantee

All Tegafur shipments are handled using validated cold-chain logistics to preserve compound integrity. Each package is sealed in moisture-proof containers with secondary protective wrapping and continuous temperature monitoring. Products are shipped via express international couriers with full tracking and insurance coverage.

Trade Assurance

We Tegafur ensure product authenticity, verified ≥99% purity, and compliance with analytical standards (HPLC, MS, and NMR). Each batch is supplied with a Certificate of Analysis (CoA). Our trade assurance policy guarantees replacement or refund for any deviation from listed specifications.

Payment Support

We Tegafur provide flexible and secure global payment options to support international research transactions. Accepted payment methods include PayPal, major credit cards (Visa, MasterCard, American Express), telegraphic transfer (T/T), and cryptocurrencies (USDT, Bitcoin, Ethereum). All transactions are protected by industry-standard encryption and verified payment gateways to ensure confidentiality and fund security.

Disclaimer

All Tegafur products listed are intended for laboratory research use only and not for human or veterinary use. They are not drugs, medical devices, or diagnostics and should not be administered to humans or animals. Researchers must handle all materials in accordance with institutional biosafety and chemical safety guidelines. The information provided is for scientific reference only and does not imply therapeutic efficacy, safety, or regulatory approval.